Request Demo

Last update 26 May 2025

Epoprostenol Sodium

Last update 26 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate, (5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid, Caripul

+ [21]

Target

PGI2 receptor

Action

agonists, inhibitors

Mechanism

PGI2 receptor agonists(Prostanoid IP receptor agonists), Platelet aggregation inhibitors

Therapeutic Areas

Respiratory DiseasesOther Diseases

Active Indication

Pulmonary Arterial HypertensionHypertension, Pulmonary

Inactive Indication

COVID-19Familial Primary Pulmonary Hypertension

Originator Organization

GSK Plc

Active Organization

Actelion Pharmaceuticals Ltd.Actelion Pharmaceuticals US, Inc.GlaxoSmithKline LLC

+ [3]

Inactive Organization

Aerogen Pharma Ltd.

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (20 Sep 1995),

Hypertension, Pulmonary

RegulationOrphan Drug (United States), Priority Review (China), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC20H32NaO5

InChIKeyWHVPOEPABJZBBY-XQYLJSSYSA-N

CAS Registry61849-14-7

Clinical Trials associated with Epoprostenol Sodium

NCT05450328

/ Not yet recruitingPhase 2IIT

Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation: A Randomized, Double-blind, Controlled Trial

In cardiac surgery, the presence of pulmonary hypertension (PH) is a prognostic factor associated with increased mortality and morbidity. In this context, one of the main causes of PH is related to reperfusion ischemia during weaning from extracorporeal circulation (CPB). One of the consequences of PH is right ventricular dysfunction. During weaning from CPB, the development of a right ventricular dysfunction is associated with increased requirements for vasopressor and inotropic agents, duration of mechanical ventilation, prolonged intensive care and hospital stay, and increased mortality compared with patients with left ventricular (LV) dysfunction. The management of patients with PH with or without right ventricular (RV) dysfunction relies on several strategies such as the administration of intravenous and inhaled agents, or mechanical ventricular support. Among those agents, the administration of inotropes or pulmonary vasodilators such as epoprostenol, milrinone and nitric oxide are among the most widely used treatments recommended by the Canadian Cardiovascular Society. At the Montreal Heart Institute, inhaled epoprostenol and milrinone are routinely administered to patients with PH or LV dysfunction in the perioperative setting. Despite the frequent use of inhaled epoprostenol and milrinone, Health Canada has not yet approved the use of these molecules.
The primary objective of this multicenter, double-blind, randomized clinical trial is to evaluate the clinical efficacy of the combined administration of inhaled epoprostenol and milrinone in a cardiac surgery setting. This trial will compare the clinical outcome of 71 patients who will receive inhaled epoprostenol and milrinone before the start of bypass surgery to 71 patients who will receive a placebo before the start of the CPB. The primary clinical outcome is the proportion of patients with an "unsuccessful" CPB weaning defined by the use of an inotrope +/- vasopressor agent or the use of mechanical circulatory support or a return to bypass grafting for hemodynamic reasons.
This clinical trial will evaluate the clinical efficacy of the combination of inhaled agents in a cardiac surgery setting. Therefore, if the results of this study are positive, the combination of inhaled epoprostenol and milrinone will optimize the management of patients with pulmonary hypertension with or without a right ventricular dysfunction.

Start Date01 Jun 2024

Sponsor / Collaborator

Montréal Heart Institute

EUCTR2022-004079-17-DK

/ Not yet recruitingPhase 2IIT

Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in mechanically ventilated patients with infectious pulmonary endotheliopathy– a multicentre randomized, placebo-controlled, blinded, investigator-initiated trial - COMBAT-ARF

Start Date20 Mar 2023

Sponsor / Collaborator

Rigshospitalet

NCT04231084

/ CompletedPhase 4IIT

Acute Hemodynamic Comparison of Inhaled Nitric Oxide and Inhaled Epoprostenol in Pulmonary Hypertension

The overarching goal of this study is to examine the acute vasoreactive response to both inhaled nitric oxide and inhaled epoprostenol across both traditionally and non-traditionally interrogated phenotypes in PH, and to further characterize the relationship of vasoreactivity to disease severity and PH phenotype.

Start Date15 Jan 2021

Sponsor / Collaborator

The Brigham & Women's Hospital, Inc.

100 Clinical Results associated with Epoprostenol Sodium

100 Translational Medicine associated with Epoprostenol Sodium

100 Patents (Medical) associated with Epoprostenol Sodium

18,790

Literatures (Medical) associated with Epoprostenol Sodium

01 Jul 2025·BIOCHIMIE

Human prostacyclin and thromboxane synthases: Molecular interactions, regulation, and pharmacology

Review

Author: Mezentsev, Yuri V ; Ivanov, Alexis S ; Ershov, Pavel V ; Yablokov, Evgeniy O

Prostanoids are lipid mediators of the human body that are involved in the inflammation and platelet aggregation. Prostacyclin is a vasodilator and inhibitor of platelet aggregation, and a product of the enzymatic reaction catalyzed by prostacyclin synthase (PTGIS). Thromboxane is a vasoconstrictor and synthesized by thromboxane synthase (TBXAS1). An imbalance of prostanoids can accompany cardio-/cerebrovascular diseases and cancers. PTGIS and TBXAS1 are clinically relevant membrane-bound enzymes of the multigene family of cytochromes P450 (CYPs), also known as CYP8A1 and CYP5A1, respectively. Particular studies of these functional antagonists will contribute to the elucidation of pathogenic mechanisms. The purpose of this work was to analyze the literature landscape over a period of 2020-2024 in the field of biological, pharmacogenomic, and pharmacological features of PTGIS and TBXAS1 as well as to explore the potential of their regulation at the post-transcriptional and post-translational levels using systems biological analysis. The review discusses recent findings on the novel aspects of both synthases established in gene knockout and overexpression experiments, current preclinical pharmacology, and potential ways of gene expression regulation. Identification of protein-protein interactions and post-translational modifications appear to be the main options for modulating PTGIS and TBXAS1 activity. The microsomal CYPs are known to form complexes with each other and direct interactions of CYP2E1 with both synthases can probably lead to modulation of their activity. Progress in the preclinical development of low molecular weight compounds as inhibitors of TBXAS1 is more prospective than PTGIS that is applied as gene therapy biologicals for in vivo production of prostacyclin due to its noticeable anticancer and vasodilator effects.

01 Jun 2025·JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Low phylloquinone intake deteriorates endothelial function in normolipidemic and dyslipidaemic mice

Article

Author: Kus, Kamil ; Sternak, Magdalena ; Zeber-Lubecka, Natalia ; Przyborowski, Kamil ; Zakrzewska, Agnieszka ; Franczyk-Zarow, Magdalena ; Princen, Hans M G ; Proniewski, Bartosz ; Kulecka, Maria ; Mohaissen, Tasnim ; Strus, Magdalena ; Kwiatkowski, Grzegorz ; Kij, Agnieszka ; Bar, Anna ; Czyzynska-Cichon, Izabela ; Buczek, Elzbieta ; Kostogrys, Renata B ; Kozien, Lucja ; Chlopicki, Stefan ; Kieronska-Rudek, Anna ; Pieterman, Elsbeth J ; Wiecek, Grazyna

While the plasma phylloquinone (PK) concentration is inversely correlated with cardiovascular risk, the involvement of PK in regulating endothelial function has not been directly investigated. Therefore, in this study we assessed the effects of short-term treatment with PK-deficient diets (5-10 weeks) on endothelial function in normolipidemic 14-week-old male C57BL/6JCmd mice and age-matched dyslipidaemic male E3L.CETP mice. Our results show that in normolipidemic mice dietary PK deficiency was associated with a marked reduction of PK levels in the plasma and liver (liquid chromatography-mass spectrometry measurements) and with impaired endothelium-dependent vasodilation assessed in vivo by magnetic resonance imaging (MRI). Dietary PK deficiency-induced endothelial dysfunction was fully reversed by PK supplementation. In dyslipidaemic E3L.CETP mice, dietary PK deficiency exacerbated preexisting endothelial dysfunction. Furthermore, dietary PK deficiency decreased menaquinone-4 (MK-4) levels in the aorta but did not affect blood coagulation (calibrated automated thrombography), microbiota composition (culturing and next-generation sequencing), and gut menaquinone production. In conclusion, our study demonstrated for the first time that sufficient dietary PK intake supports endothelial function in normolipidemic and dyslipidaemic mice indicating nutritional significance of dietary PK in the maintenance of endothelial function in humans.

01 Jun 2025·British Journal of Pharmacology

Engineered pulmonary artery tissues for measuring contractility, drug testing and disease modelling

Article

Author: Wojciak‐Stothard, Beata ; Fellows, Adam L. ; Barnett, Harry ; Miller, David ; Ainscough, Alexander J. ; Leung, Venus ; Wilkins, Martin R. ; Quigley, Kate ; Mayr, Manuel

Abstract:

Background and Purpose:

Vasoreactivity of pulmonary arteries regulates blood flow through the lungs. Excessive constriction of these vessels contributes to pulmonary arterial hypertension (PAH), a progressive and incurable condition, resulting in right heart failure. The search for new and improved drug treatments is hampered by laboratory models that do not reproduce the vasoactive behaviour of healthy and diseased human arteries.

Experimental Approach:

We have developed an innovative technique for producing miniature, three‐dimensional arterial structures that allow proxy evaluation of human pulmonary artery contractility. These “engineered pulmonary artery tissues” or “EPATs” are fabricated by suspending human pulmonary artery vascular smooth muscle cells (VSMCs) in fibrin hydrogels between pairs of silicone posts, located on custom‐made racks, in 24‐well culture plates.

Key Results:

EPATs exhibit rapid, robust and reproducible contraction responses to vasoconstrictors (KCl, ET‐1, U46619) as well as relaxation responses to clinically approved PAH vasodilatory drugs that target several signalling pathways, such as bosentan, epoprostenol, selexipag and imatinib. EPATs composed of pulmonary artery VSMCs from PAH patients exhibit enhanced contraction to vasoconstrictors and relaxation in response to vasodilators. We also demonstrate the incorporation of endothelial cells into EPATs for the measurement of endothelium‐dependent dilatory responses.

Conclusion and Implications:

We demonstrate the capacity and suitability of EPATs for studying the contractile behaviour of human arterial cells and preclinical drug testing. This novel biomimetic platform has the potential to dramatically improve our understanding and treatment of cardiovascular disease.

News (Medical) associated with Epoprostenol Sodium

23 May 2025

·cerenoscientific.com

Cereno Scientific receives endorsement from FDA on plans for Phase IIb trial of CS1 in rare disease pulmonary arterial hypertension (PAH)

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the US Food & Drug Administration (FDA) provided endorsement of the plans for the Phase IIb trial of CS1 as noted by the official meeting minutes from the Type C-meeting held on April 21. The next clinical development step of CS1 is a larger, placebo-controlled Phase IIb trial aiming to further evaluate the encouraging efficacy signs including reverse vascular remodeling and improvement of right heart function as observed in the Phase IIa trial. “This is a very exciting milestone for our pipeline. Receiving an FDA endorsement for the CS1 program in PAH at this stage in development is paving the way for further interactions regarding upcoming Phase IIb and pivotal Phase III trials. The plans for the Phase IIb trial are in alignment with the expectations of the FDA, meaning that we have high confidence that the Phase IIb trial design will include the relevant criteria contributing to the development program’s marketing approval process. We are now continuing steps for preparations ahead of the Phase IIb trial in PAH, with a target of initiating the trial in H1 2026,” said Rahul Agrawal, Chief Medical Officer (CMO) and Head of R&D at Cereno Scientific. “The endorsement from the FDA for CS1 validates that the development plans have sound rationale to be able to support documentation for future marketing approval and adds credibility to our scientific and clinical capabilities. These are important factors in the dialogues we have with potential partners, but also other stakeholders we interact with such as collaborators, investors and the scientific community. We are keen to progress towards the initiation of the Phase IIb trial to further evaluate CS1 as a PAH treatment with favorable safety and tolerability and disease-modifying capacity. Our ultimate ambition is to be able to develop a treatment that could enhance and extend life of patients suffering from this devastating and fatal disease,” said Sörensen, CEO at Cereno Scientific. Drug candidate CS1 is a well-tolerated oral therapy with a favorable safety profile and showed signals of disease-modifying effects as observed in a Phase IIa trial in patients with the rare disease pulmonary arterial hypertension (PAH). The aim for CS1 is to offer an effective disease-modifying treatment with the ability to enhance quality of life and extend life for PAH patients. Unlike standard therapy that focus on managing symptoms, CS1 represents a novel therapeutic approach by targeting the root mechanisms of PAH. Specifically, CS1 aims to reverse the pathological vascular remodeling of the small pulmonary arteries. A successful Phase IIa trial was concluded in 2024. Insights into the long-term use of CS1 are being gathered in an expanded access program with 10 patients from the Phase IIa trial. Preparations are currently underway for a larger placebo-controlled Phase IIb trial to continue advancing CS1 toward regulatory approval and wider patient access. The Phase IIb trial is planned to be initiated in H1 2026. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

Phase 2Phase 1

13 May 2025

·cerenoscientific.com

Cereno Scientific presented CS1’s Phase IIa trial results at the 5th Baltic Pulmonary Hypertension Conference 2025

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that an oral presentation titled “Exploratory outcomes of CS1 in Pulmonary Arterial Hypertension: Phase 2A, Prospective, Randomized, Open-Label, Multicenter Trial” was presented at the 5th Baltic Pulmonary Hypertension Conference 2025 on May 9, 2025, in Kaunas, Lithuania. The data presented in an abstract at the Baltic PH Conference highlighted key results from the Phase IIa trial of CS1 in PAH. The primary endpoint of safety and tolerability was met without any drug-related safety concerns. After 12 weeks, REVEAL Risk Score 2.0 was improved from baseline in 40.9% of patients and stable in a further 31.8% of patients. A total of 31.8% and 54.5% of patients improved or maintained their NYHA/WHO functional class, respectively. The majority of patients (71%) showed an improvement in quality of life as measured by the Minnesota Living with Heart Failure Questionnaire (MLHFQ). The abstract concludes that the findings from the Phase IIa trial suggest that treatment with CS1 in patients with pulmonary arterial hypertension (PAH) improve risk score, functional class and quality of life. The conclusion states that CS1 warrants further study. Tatiane Abreu Dall’Agnol, Medical Director at Cereno Scientific, presented the abstract at the conference. “I am pleased that we have now presented the results from our Phase IIa trial of CS1 in PAH to the scientific community in a formal setting. The Phase IIa trial demonstrated that CS1 is well-tolerated and has a favorable safety profile. Importantly, we observed encouraging signals of reverse vascular remodeling. These exploratory efficacy findings are promising and we are now planning a larger, placebo-controlled Phase IIb trial in PAH to further evaluate these effects,” said Rahul Agrawal, CMO and Head of R&D at Cereno Scientific. “There remains a profound unmet need in PAH for treatments that do more than just manage symptoms. With CS1, we are developing a potential first-in-class, disease-modifying therapy that targets the root mechanisms driving PAH — pathological vascular remodeling and right heart dysfunction. The favorable safety and tolerability profile, along with encouraging efficacy signals observed in our clinical development to date, reinforce CS1’s potential to transform how PAH is treated. We are proud to continue advancing this innovation with the goal of meaningfully improving the lives of patients living with this devastating disease,” said Sten R. Sörensen, CEO of Cereno Scientific. A publication of the Phase IIa trial results of CS1 in PAH is in development with the aim be published during H2 2025. Abstract details: Benza, R., et al. (2025). Exploratory outcomes of CS1 in pulmonary arterial hypertension: Phase 2A, prospective, randomized, open-label, multicenter trial Raymond [Abstract]. Abstracts book of the 5th Baltic Pulmonary Hypertension Conference 2025, Kaunas, Lithuania. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 Sten R. Sörensen, CEO Email: sten.sorensen@cerenoscientific.com Phone: +46 73-374 03 74 About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

Phase 2Clinical ResultPhase 1

07 May 2025

·cerenoscientific.com

Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on May 10, 2025

The Nomination Committee of Cereno Scientific AB (publ) (the “Company”) has today decided to propose a new Board of Directors at the Annual General Meeting on June 10, 2025, with particular expertise in M&A/partnering and business development (BD). The Nomination Committee’s proposal means that Jeppe Øvlesen is proposed as the new Chairman of the Board, that Moi Brajanovic is proposed to be newly elected as a Board member and that Joakim Söderström is not proposed to be a member of the Board. The other Board members Anders Svensson, Gunnar Olsson and Sten R. Sörensen are proposed to be re-elected. The Nomination Committee, in accordance with the principles adopted by the previous Annual General Meeting, consists of Andreas Ejlegård (Chairman), Joakim Söderström and Björn Dahlöf. The Nomination Committee proposes the following Board: re-election of Board members Anders Svensson, Jeppe Øvlesen, Gunnar Olsson and Sten R. Sörensen and new election of board member Moi Brajanovic. Jeppe Øvlesen is proposed to be elected as Chairman of the Board (new election). Statement from the Nomination Committee Chairman Andreas Ejlegård: "The Nomination Committee has noted that the company is now entering a new phase with an increased focus on M&A and BD. Joakim Söderström has led the work of the Board in an exemplary manner during the last two terms of office. Although he has been available to the Nomination Committee for re-election, the Nomination Committee believes that a change in leadership on the Board is important to optimize the company's conditions in the upcoming phase. Against this background, the Nomination Committee proposes a new composition of the Board to strengthen the opportunities to achieve the company's strategic goals. Jeppe Øvlesen is an internationally recognized authority in dealmaking and has the experience and competence required to successfully lead this work forward. With Moi Brajanovic as a new member, the Board is provided with important expertise in business development and transactions - two key areas to drive the company to realize its strategic goals.” Moi Brajanovic (born 1987) holds a degree of master in economics with a focus on Business Administration from the School of Business, Economics and Law at the University of Gothenburg. Moi has extensive international experience from the finance sector, with a strong background in business development, due diligence and transactions (M&A). During his career, Moi has led complex risk and capital management assignments for international financial institutions. Moi is currently Managing Director at Advisense, a leading European company within governance, risk and compliance. The Nomination Committee’s other proposals will be presented in the notice of the Annual General Meeting that the Company plans to publish on Friday, May 9, 2025. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 This information is information that Cereno Scientific AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14:00 (CET) on May 7, 2025. About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

Phase 1Phase 2Executive ChangeClinical Result

100 Deals associated with Epoprostenol Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D01337	Epoprostenol Sodium	B01AC09	DB01240

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pulmonary Arterial Hypertension	Japan	GlaxoSmithKline KK	25 Jan 1999
Hypertension, Pulmonary	United States	GlaxoSmithKline LLC	20 Sep 1995

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Familial Primary Pulmonary Hypertension	Phase 3	Belgium	Actelion Pharmaceuticals US, Inc.	01 Mar 2011
Familial Primary Pulmonary Hypertension	Phase 3	Canada	Actelion Pharmaceuticals US, Inc.	01 Mar 2011
Familial Primary Pulmonary Hypertension	Phase 3	France	Actelion Pharmaceuticals US, Inc.	01 Mar 2011
Familial Primary Pulmonary Hypertension	Phase 3	Italy	Actelion Pharmaceuticals US, Inc.	01 Mar 2011
Familial Primary Pulmonary Hypertension	Phase 3	Netherlands	Actelion Pharmaceuticals US, Inc.	01 Mar 2011
Familial Primary Pulmonary Hypertension	Phase 3	Spain	Actelion Pharmaceuticals US, Inc.	01 Mar 2011
COVID-19	Phase 2	United States	Aerogen Pharma Ltd.	15 Sep 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02251041 (CAPITL, CTgov)	Phase 2	Reperfusion Injury	143	C1-Inhibitor+Epoprostenol+Infliximab+Melatonin+Alfa-tocopherol+Human recombinant erythropoietin+Glutathione	gvyyjmogso = iqqfhzuzqc nssfpotmwm (rzuzzmeijr, rgobzzsxfi - ltmncnijzn) View more	-	23 Aug 2024
ATS2024	Not Applicable	Pulmonary Arterial Hypertension	-	Intravenous prostacyclin (epoprostenol or treprostinil)	rqexutwqtt(jfsmfwdaak) = zexmvoyvfm owhpmenria (ggvwimhdsh, 307) View more	-	19 May 2024
				Oral prostacyclin	rqexutwqtt(jfsmfwdaak) = afffzreylc owhpmenria (ggvwimhdsh, 47.2)
ATS2024	Not Applicable	Heart Failure	-	Epoprostenol	lyjyorayxw(lwwvtgzuoh) = ecblmoxxdl tpdbwodvxd (kaskubtgmu ) View more	-	19 May 2024
NCT03081052 (Pubmed)	Phase 4	-	231	Inhaled Epoprostenol	fqipumwkzd(znntwrosox) = hbecvjyzhy vomtivstmk (dztgvypcfz )	-	04 Jul 2023
				Nitric Oxide	fqipumwkzd(znntwrosox) = xmpfubtktp vomtivstmk (dztgvypcfz )
PSAT054 (ENDO2022)	Not Applicable	ACTH Deficiency, Isolated	-	Epoprostenol	alirpmmbie(xdtxzyhcpj) = vuteqzpajj kmawuvnyna (umtitoorzq )	-	01 Nov 2022
ATS2022	Not Applicable	COVID-19	-	HFNC+iEPO	cwatxeudqs(rwfkqkvsna) = vppwzszacu buvsytwsah (ymwfmrlckm ) View more	-	15 May 2022
				HFNC alone	skclcfxnct(cagbmcumic) = qwozrzyhwu cdevyiopic (nxyuowjpmp )
ATS2022	Not Applicable	Pulmonary Arterial Hypertension	-	Self-admixed infused prostacyclins	uqwoelssmr(uqosjngcmi) = hoayxickkm ftnivptmvo (dgmuymjykm )	-	15 May 2022
				Pharmacy-prepared admixture	uqwoelssmr(uqosjngcmi) = qqqyiehovy ftnivptmvo (dgmuymjykm )
NCT03081052 (INSPIRE-FLO, CTgov)	Phase 4	Lung Diseases \| Heart Failure \| Graft Rejection	519	iNO (Lung Transplant With iNO)	cpvjwqcvlf = lztjrdsyse kityblrocs (nnobrejwal, awcttcplcv - mltponldcb) View more	-	10 Mar 2022
				iEPO (Lung Transplant With iEPO)	cpvjwqcvlf = lgmejkzitp kityblrocs (nnobrejwal, rlrfhcfyse - pzybjttnxz) View more
NCT01462565 (CTgov)	Phase 4	Pulmonary Arterial Hypertension	16	Epoprostenol Sodium	fquozojtzs(dnuxvrfaka) = ieqedcqijo rushwkasge (wlejrnhoey, 3.6593) View more	-	16 Oct 2017
NCT01717209 (CTgov)	Phase 4	Heart Failure	14	Nitric Oxide+Prostacyclin	lsqwdvjwyb(eogkautodh) = xfbdpudcfr vvkxzxgknp (wrkdqaoytv, hamkmkekcy - qbveoctghd) View more	-	09 Oct 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis